5-(Chloromethyl)-2-(trifluoromethyl)-1,3,4-oxadiazole

Catalog No. :
ACTKDE536
CAS No. :
723286-98-4
Molecular Formula :
C4H2ClF3N2O
Molecular Weight :
186.52

IUPAC Name:2-(chloromethyl)-5-(trifluoromethyl)-1,3,4-oxadiazole

5-(Chloromethyl)-2-(trifluoromethyl)-1,3,4-oxadiazole structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g98%$67.00Login to see priceIn stockInquiry
10g98%$81.00Login to see priceIn stockInquiry
25g98%$202.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-(Chloromethyl)-2-(trifluoromethyl)-1,3,4-oxadiazole
IUPAC Name2-(chloromethyl)-5-(trifluoromethyl)-1,3,4-oxadiazole
MDL No.MFCD09699166
Molecular FormulaC4H2ClF3N2O
Molecular Weight186.52
SMILESFC(C1=NN=C(CCl)O1)(F)F
InChI KeyGPXSXZGMVOSWMN-UHFFFAOYSA-N
Synonym723286-98-4 | 2-(chloromethyl)-5-(trifluoromethyl)-1,3,4-oxadiazole | 5-(Chloromethyl)-2-(trifluoromethyl)-1,3,4-oxadiazole | 5-(TRIFLUOROMETHYL)-2-(CHLOROMETHYL)-1,3,4-OXADIAZOLE | C4H2ClF3N2O | 2-CHLOROMETHYL-5-TRIFLUOROMETHYL-[1,3,4]OXADIAZOLE | 2-Chloromethyl-5-t
CAS No.723286-98-4
PubChem CID10442445

Safety Data

Pictogram
CorrosiveHarmful or irritant
Signal Word
Gefahr
Hazard Statement(s)
H302-H314
Precautionary Statement(s)
P280-P305+P351+P338-P310

Synthetic Route by SureRoute

1. ACTKDE536 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACKMEY092 route compound structure diagram
    ACKMEY092762240-99-3 In Stock
  2. Then
  3. ACTKDE536 route product structure diagram
    ACTKDE536723286-98-4 In Stock
Inquiry

2. ACTKDE536 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACBAUS147 route compound structure diagram
    ACBAUS1472923-16-2 In Stock
  4. Then
  5. ACTKDE536 route product structure diagram
    ACTKDE536723286-98-4 In Stock
Inquiry

Comments (0)